347 reports of this reaction
1.2% of all CENEGERMIN BKBJ reports
#20 most reported adverse reaction
INTENTIONAL PRODUCT MISUSE is the #20 most commonly reported adverse reaction for CENEGERMIN BKBJ, manufactured by Domp farmaceutici S.p.A.. There are 347 FDA adverse event reports linking CENEGERMIN BKBJ to INTENTIONAL PRODUCT MISUSE. This represents approximately 1.2% of all 28,659 adverse event reports for this drug.
Patients taking CENEGERMIN BKBJ who experience intentional product misuse should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INTENTIONAL PRODUCT MISUSE is a less commonly reported adverse event for CENEGERMIN BKBJ, but still significant enough to appear in the safety profile.
In addition to intentional product misuse, the following adverse reactions have been reported for CENEGERMIN BKBJ:
The following drugs have also been linked to intentional product misuse in FDA adverse event reports:
INTENTIONAL PRODUCT MISUSE has been reported as an adverse event in 347 FDA reports for CENEGERMIN BKBJ. This does not prove causation, but indicates an association observed in post-market surveillance data.
INTENTIONAL PRODUCT MISUSE accounts for approximately 1.2% of all adverse event reports for CENEGERMIN BKBJ, making it a notable side effect.
If you experience intentional product misuse while taking CENEGERMIN BKBJ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.